143915-15-5

Basic information

• Product Name: Carbamic acid, (1-formylpropyl)-, phenylmethyl ester, (S)-
• CAS NO: 143915-15-5
• Molecular Formula: C12H15NO3
• Molecular Weight: 221.256
• Mol File: 143915-15-5.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (1-formylpropyl)-, phenylmethyl ester, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (1-formylpropyl)-, phenylmethyl ester, (S)-(143915-15-5)
• EPA Substance Registry System: Carbamic acid, (1-formylpropyl)-, phenylmethyl ester, (S)-(143915-15-5)

Safety Data

• Hazardous Substances Data: 143915-15-5(Hazardous Substances Data)

Upstream product

• 42918-86-5 (S)-2-(((benzyloxy)carbonyl)amino)butanoic acid 
• 501-53-1 benzyl chloroformate 
• 22373-14-4 [(1S)-1-(hydroxymethyl)propyl]carbamic acid benzyl ester 
• 160069-74-9 [(R)-1-(4,4,6,6-Tetramethyl-[1,3]dioxan-2-yl)-propyl]-carbamic acid benzyl ester 
• 94202-79-6 (R,E)-benzyl hex-4-en-3-ylcarbamate 
• 73395-16-1 benzyl (1R)-1-(hydroxymethyl)propylcarbamate 

Downstream Products

• 1352439-98-5 C₁₅H₂₁NO₆ 
• 1352439-99-6 C₁₅H₂₁NO₆ 
• 913180-78-6 {1-[(4-trifluoromethoxy-phenylamino)-methyl]-propyl}-carbamic acid benzyl ester 
• 143914-90-3 (E)-(S)-4-Benzyloxycarbonylamino-2-methyl-hex-2-enoic acid ethyl ester 

Relevant articles and documents

Oxazolidin-2-one-Pyrimidine Derivatives

The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

Cyclic amine compounds

The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhance

Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers

The synthesis and structure-activity relationship of a series of arylaminoethyl amide cathepsin S inhibitors are reported. Optimization of P3 and P2 groups to improve overall physicochemical properties resulted in significant improvements in oral bioavail